GlaxoSmithKline Plc and Vir Biotechnology said on Monday final results from a late-stage study of their monoclonal antibody confirmed it significantly reduced hospitalisation and death among high-risk Covid-19 patients when given early in the disease.

The treatment, sotrovimab, received an emergency use authorisation from the US Food and Drug Administration in May, while the European Union's drug regulator has also backed it.

The drugmakers also said...